Company Introduction And Thesis
Cara Therapeutics Inc. (CARA) is a small-cap biopharmaceutical company whose focus revolves around pruritus (severe itch) and pain, specifically through selective targeting and activation of kappa-opioid receptors. The company's main pipeline candidate is KORSUVA (or CR845, a peripherally-acting kappa-opioid receptor agonist) injection for chronic kidney disease-associated pruritus (CKD-aP) in dialysis patients. The company is also exploring oral KORSUVA for pruritus, intravenous KORSUVA for post-op pain, oral KORSUVA for chronic pain, and oral CR701 (cannabinoid receptor type 2 agonist) for chronic pain.
Pruritus, acute pain, and chronic pain have common cellular/molecular etiologies that are the result of inflammatory factor/neuropeptide release and subsequent interaction between immune cells and nociceptive neurons, with downstream effects at peripheral vasculature and central nervous system pain pathways.

